Beth Harrison

Jun 2, 2023 | nature.com | Ana C. Garrido-Castro |Faina Nakhlis |Laura Warren |Beth Harrison |Sara M. Tolaney |Beth Overmoyer

AbstractInflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer that presents as de novo metastatic disease in 20–30% of cases, with one-third of cases demonstrating HER2-positivity. There has been limited investigation into locoregional therapy utilization following HER2-directed systemic therapy for these patients, and their locoregional progression or recurrence (LRPR) and survival outcomes.